Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising on...

Full description

Saved in:
Bibliographic Details
Main Authors Coyle, Anthony John, Hopson, Kristen Park, Aliprantis, Antonios O, Root, Adam Reid, Costello, Zachary Kohl, Reif, Karin Alma Frieda, Phennicie, Ryan Terrell, Ramos, Alexis Hiram, Dinic, Lana
Format Patent
LanguageEnglish
Published 08.10.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to a thymic stromal lymphopoietin (TSLP) (e.g., a full-length human TSLP). The disclosure also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating a TSLP-associated disease or condition.
Bibliography:Application Number: US202318356891